We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




LabCorp Purchases Genzyme's Genetic Testing Business

By LabMedica International staff writers
Posted on 15 Dec 2010
Genzyme Corporation (Cambridge, MA, USA) has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings (Burlington, NC, USA) for US$925 million in cash.

Under the final terms of the agreement, LabCorp purchased substantially all of the assets of the Genzyme Genetics business, including testing services, technology, intellectual property rights, and the rights to continue operations at the unit's nine genetic testing laboratories. More...
All employees of Genzyme Genetics were offered similar positions at LabCorp.

Genzyme is a leading biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant, and immune disease. In the year 2010, the company was named to the Fortune 500.

The sale to LabCorp represents the completion of the first of three planned divestitures previously announced by Genzyme. Earlier in November 2010, the company entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash. The company also plans to divest its Pharmaceuticals business. Proceeds from the three transactions may be used to finance the remaining half of the Genzyme's planned $2 billion stock repurchase.

Complex reproductive and oncology testing services are also provided by Genzyme Genetics. "Closing the acquisition of Genzyme Genetics firmly establishes LabCorp as the premier genetics and oncology laboratory in the United States and further strengthens LabCorp's leadership position in personalized medicine. We are excited to welcome the Genzyme Genetics personnel to our LabCorp family," said David P. King, chairman and CEO of LabCorp.

Related Links:

Genzyme Corporation
Laboratory Corporation of America Holdings




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
ESR Analyzer
TEST1 2.0
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.